^(99)Tc^mN-CHPDTC的制备及生物分布

PREPARATION AND BIODISTRIBUTION OF ^(99)Tc^mN-CHPDTC

以SnCl2 ·2H2 O为还原剂 ,N 甲基二硫代肼甲酸甲酯 (DTCZ)为N3- 离子提供体制备[99TcmN]int2 + 中间体 ,然后与配体二水·N 环庚基 二硫代氨基甲酸钠 (CHPDTC)发生配体交换反应 ,得到放化纯大于 90 %的99TcmN CHPDTC配合物。99TcmN CHPDTC在制备后放置 7h放化纯不变 ,分配比lgD =1 5 0。小鼠体内生物分布结果表明 ,99TcmN CHPDTC有较高心肌摄取和较好的心肌滞留。在注射后 5 ,30 ,60min时 ,心肌摄取量 (ID/ (%·g- 1) )分别为 17 17,16 82 ,19 18。在注射后 60min时 ,R(心 /血 ) ,R(心 /肺 ) ,R(心 /肝 )比值分别为 7 10 ,1 4 3,0 4 1。

Tc mN CHPDTC(CHPDTC:N cycloheptyl dithiocarbamate dihydrate) is prepared through a two step ligand exchange reaction with SnCl 2·2H 2O as reduction agent and DTCZ(N methyl, S methyl dithiocarbazate) as a donor of nitride nitrogen atom (N 3- ). The radiochemical purity (RCP) of the product is over 90 % by TLC. It is stable over 7 h at room temperature. The lg D value is 1 50. The biodistribution results in mice indicate the complex has high myocardial uptake and good retention. The heart uptake (ID/(%·g -1 )) is 17 17, 16 82 and 19 18 at 5,30 and 60 min post injection. R (heart/blood), R (heart/lung) and R (heart/liver) are 7 10, 1 43 and 0 41 at 60 min post injection respectively. The results for the complex suggest that it will be potentially useful as a myocardial perfusion imaging agent.